NCT01209130 (Clinical Trial / Pinatuzumab Vedotin / DCDT2980S / RG-7593)

Study Title
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin’s Lymphoma (NCT01209130)

Trial Description
This is a Phase I, multicenter, open-label, dose-escalation study of DCDT2980S (pinatuzumab vedotin or RG-7593) administered by intravenous (IV) infusion to patients with relapsed or refractory hematologic malignancies. In addition, at selected sites, DCDT2980S will be studied in combination with rituximab.

This trial is sponsored by Genentech. [1]

Study Data

  • Condition:
  • Interventions:
    • Drugs used in this trial
  • Phase: I
  • Enrollment: 91
  • Start: October 2010
  • Completion: March 2015
  • Last verified: July 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 13, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.